News

5N Plus Inc. (TSX:VNP) (“5N Plus” or the “Company”), a leading global producer of specialty semiconductors and performance materials, today announced that it has entered into an agreement with AZUR SPACE Solar Power GmbH (“AZUR”) pursuant to which 5N Plus would acquire all of the issued and outstanding shares of AZUR (the “Transaction”). The Transaction is subject to the customary closing conditions, including regulatory approvals. 

5N Plus Inc. (TSX:VNP) (“5N Plus” or the “Company”), a leading global producer of specialty chemicals and engineered materials, today announced the renewal of its $79 million senior secured multi-currency, revolving and syndicated credit facility. The agreement includes a contingent option to expand the facility to $124 million.

5N Plus Inc. (TSX:VNP) (“5N Plus” or the “Company”), a leading global producer of engineered materials and specialty chemicals, today reported financial results for the fourth quarter and fiscal year ended December 31, 2020. All amounts are expressed in U.S. dollars.

5N Plus Inc. (“5N Plus” or the “Company”), a leading global producer of specialty chemicals and engineered materials, announced today that it has entered into a strategic agreement with Bozeman, Montana-based Microbion Corporation (“Microbion”), aimed at furthering the development of Microbion’s new class of antibiotic and antibiofilm drugs. Under the terms of the agreement, 5N Plus has taken an equity stake in Microbion and will assume responsibility for the manufacturing of Bismuth-based Active Pharmaceutical Ingredients (API) required in Microbion’s family of drug products currently under development, including Pravibismane, the API in the company’s lead drug product.

5N Plus Inc. (“5N Plus”), a leading global producer of specialty chemicals and engineered materials, and Microbion Corporation (“Microbion”), a clinical-stage pharmaceutical company focused on the development of compounds for the treatment of resistant and difficult-to-treat infections, jointly announced today that the parties have entered into a strategic relationship for the development, manufacturing and commercial drug substance supply of Microbion’s new class of antibiotic and antibiofilm drugs.